Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Copanlisib→

Copanlisib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1032568-63-0
PubChem CID
135565596
Molecular formula
C23H28N8O4
Molecular weight
480.5 g/mol
Drug class
Phosphatidylinositol-3-kinase (PI3K) inhibitortargeted antineoplastic kinase inhibitor (withdrawn US indication)
Mechanism of action
Inhibits class I PI3K isoforms, with activity against PI3K-alpha and PI3K-delta, reducing downstream AKT signalling involved in tumour-cell proliferation and survival.
Indications / reported uses
  • Historical US indication: treatment of adults with relapsed follicular lymphoma after at least two systemic therapies. The US approval for ALIQOPA was withdrawn in 2023 following voluntary withdrawal; do not present this as a current US-authorised treatment.

Identification source: PubChem record (CID 135565596). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Copanlisib Environmental Risk Assessment (ERA) (the Copanlisib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.